Estimation	O
of	O
the	O
HIV	B:C0019704
-	I:C0019704
1	I:C0019704
backward	O
mutation	O
rate	O
from	O
transmitted	O
drug	I:C0013203
-	I:C0013203
resistant	I:C0013203
strains	O

Estimation	O
of	O
the	O
HIV	O
-	I:C0019704
1	I:C0019704
backward	B:C0439784
mutation	O
rate	O
from	O
transmitted	O
drug	I:C0013203
-	I:C0013203
resistant	I:C0013203
strains	O

Estimation	O
of	O
the	O
HIV	O
-	I:C0019704
1	I:C0019704
backward	O
mutation	O
rate	O
from	O
transmitted	B:C0013203
drug	I:C0013203
-	I:C0013203
resistant	I:C0013203
strains	O

One	O
of	O
the	O
serious	O
threats	O
facing	O
the	O
administration	O
of	O
antiretroviral	B:C1963724
therapy	I:C1963724
to	O
human	O
immunodeficiency	I:C0019704
virus	I:C0019704
(	O
HIV	O
-	I:C0019704
1	I:C0019704
)	O
infected	O
patients	O
is	O
the	O
reported	O
increasing	O
prevalence	O
of	O
transmitted	O
drug	I:C0013203
resistance	I:C0013203
.	O

One	O
of	O
the	O
serious	O
threats	O
facing	O
the	O
administration	O
of	O
antiretroviral	O
therapy	I:C1963724
to	O
human	B:C0019704
immunodeficiency	I:C0019704
virus	I:C0019704
(	O
HIV	O
-	I:C0019704
1	I:C0019704
)	O
infected	O
patients	O
is	O
the	O
reported	O
increasing	O
prevalence	O
of	O
transmitted	O
drug	I:C0013203
resistance	I:C0013203
.	O

One	O
of	O
the	O
serious	O
threats	O
facing	O
the	O
administration	O
of	O
antiretroviral	O
therapy	I:C1963724
to	O
human	O
immunodeficiency	I:C0019704
virus	I:C0019704
(	O
HIV	B:C0019704
-	I:C0019704
1	I:C0019704
)	O
infected	O
patients	O
is	O
the	O
reported	O
increasing	O
prevalence	O
of	O
transmitted	O
drug	I:C0013203
resistance	I:C0013203
.	O

One	O
of	O
the	O
serious	O
threats	O
facing	O
the	O
administration	O
of	O
antiretroviral	O
therapy	I:C1963724
to	O
human	O
immunodeficiency	I:C0019704
virus	I:C0019704
(	O
HIV	O
-	I:C0019704
1	I:C0019704
)	O
infected	B:C2363741
patients	O
is	O
the	O
reported	O
increasing	O
prevalence	O
of	O
transmitted	O
drug	I:C0013203
resistance	I:C0013203
.	O

One	O
of	O
the	O
serious	O
threats	O
facing	O
the	O
administration	O
of	O
antiretroviral	O
therapy	I:C1963724
to	O
human	O
immunodeficiency	I:C0019704
virus	I:C0019704
(	O
HIV	O
-	I:C0019704
1	I:C0019704
)	O
infected	O
patients	O
is	O
the	O
reported	O
increasing	O
prevalence	O
of	O
transmitted	B:C0013203
drug	I:C0013203
resistance	I:C0013203
.	O

However	O
,	O
given	O
that	O
HIV	B:C0019704
-	I:C0019704
1	I:C0019704
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
are	O
often	O
less	O
fit	O
than	O
the	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
,	O
it	O
is	O
expected	O
that	O
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
that	O
are	O
present	O
during	O
the	O
primary	O
phase	O
of	O
the	O
HIV	O
-	I:C2363741
1	I:C2363741
infection	I:C2363741
are	O
replaced	O
by	O
the	O
fitter	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
.	O

However	O
,	O
given	O
that	O
HIV	O
-	I:C0019704
1	I:C0019704
drug	B:C0013203
-	I:C0013203
resistant	I:C0013203
strains	O
are	O
often	O
less	O
fit	O
than	O
the	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
,	O
it	O
is	O
expected	O
that	O
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
that	O
are	O
present	O
during	O
the	O
primary	O
phase	O
of	O
the	O
HIV	O
-	I:C2363741
1	I:C2363741
infection	I:C2363741
are	O
replaced	O
by	O
the	O
fitter	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
.	O

However	O
,	O
given	O
that	O
HIV	O
-	I:C0019704
1	I:C0019704
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
are	O
often	O
less	O
fit	O
than	O
the	O
wild	B:C1883559
-	I:C1883559
type	I:C1883559
strains	O
,	O
it	O
is	O
expected	O
that	O
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
that	O
are	O
present	O
during	O
the	O
primary	O
phase	O
of	O
the	O
HIV	O
-	I:C2363741
1	I:C2363741
infection	I:C2363741
are	O
replaced	O
by	O
the	O
fitter	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
.	O

However	O
,	O
given	O
that	O
HIV	O
-	I:C0019704
1	I:C0019704
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
are	O
often	O
less	O
fit	O
than	O
the	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
,	O
it	O
is	O
expected	O
that	O
drug	B:C0013203
-	I:C0013203
resistant	I:C0013203
strains	O
that	O
are	O
present	O
during	O
the	O
primary	O
phase	O
of	O
the	O
HIV	O
-	I:C2363741
1	I:C2363741
infection	I:C2363741
are	O
replaced	O
by	O
the	O
fitter	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
.	O

However	O
,	O
given	O
that	O
HIV	O
-	I:C0019704
1	I:C0019704
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
are	O
often	O
less	O
fit	O
than	O
the	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
,	O
it	O
is	O
expected	O
that	O
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
that	O
are	O
present	O
during	O
the	O
primary	O
phase	O
of	O
the	O
HIV	B:C2363741
-	I:C2363741
1	I:C2363741
infection	I:C2363741
are	O
replaced	O
by	O
the	O
fitter	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
.	O

However	O
,	O
given	O
that	O
HIV	O
-	I:C0019704
1	I:C0019704
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
are	O
often	O
less	O
fit	O
than	O
the	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
,	O
it	O
is	O
expected	O
that	O
drug	O
-	I:C0013203
resistant	I:C0013203
strains	O
that	O
are	O
present	O
during	O
the	O
primary	O
phase	O
of	O
the	O
HIV	O
-	I:C2363741
1	I:C2363741
infection	I:C2363741
are	O
replaced	O
by	O
the	O
fitter	O
wild	B:C1883559
-	I:C1883559
type	I:C1883559
strains	O
.	O

This	O
replacement	O
of	O
HIV	B:C1836231
-	I:C1836231
1	I:C1836231
resistant	I:C1836231
mutations	O
involves	O
the	O
emergence	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
by	O
a	O
process	O
of	O
backward	O
mutation	O
.	O

This	O
replacement	O
of	O
HIV	O
-	I:C1836231
1	I:C1836231
resistant	I:C1836231
mutations	B:C0026882
involves	O
the	O
emergence	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
by	O
a	O
process	O
of	O
backward	O
mutation	O
.	O

This	O
replacement	O
of	O
HIV	O
-	I:C1836231
1	I:C1836231
resistant	I:C1836231
mutations	O
involves	O
the	O
emergence	O
of	O
wild	B:C1883559
-	I:C1883559
type	I:C1883559
strains	O
by	O
a	O
process	O
of	O
backward	O
mutation	O
.	O

This	O
replacement	O
of	O
HIV	O
-	I:C1836231
1	I:C1836231
resistant	I:C1836231
mutations	O
involves	O
the	O
emergence	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
by	O
a	O
process	O
of	O
backward	B:C0439784
mutation	O
.	O

This	O
replacement	O
of	O
HIV	O
-	I:C1836231
1	I:C1836231
resistant	I:C1836231
mutations	O
involves	O
the	O
emergence	O
of	O
wild	O
-	I:C1883559
type	I:C1883559
strains	O
by	O
a	O
process	O
of	O
backward	O
mutation	B:C0026882
.	O

How	O
quickly	O
the	O
replacement	O
happens	O
is	O
dependent	O
on	O
the	O
class	O
of	O
HIV	B:C0019704
-	I:C0019704
1	I:C0019704
mutation	O
group	O
.	O

How	O
quickly	O
the	O
replacement	O
happens	O
is	O
dependent	O
on	O
the	O
class	O
of	O
HIV	O
-	I:C0019704
1	I:C0019704
mutation	B:C0026882
group	O
.	O

We	O
estimate	O
the	O
backward	B:C0439784
mutation	O
rates	O
and	O
relative	O
fitness	O
of	O
various	O
mutational	O
groups	O
known	O
to	O
confer	O
HIV	O
-	I:C0019704
1	I:C0019704
drug	O
resistance	I:C0013203
.	O

We	O
estimate	O
the	O
backward	O
mutation	O
rates	O
and	O
relative	O
fitness	O
of	O
various	O
mutational	B:C0026882
groups	O
known	O
to	O
confer	O
HIV	O
-	I:C0019704
1	I:C0019704
drug	O
resistance	I:C0013203
.	O

We	O
estimate	O
the	O
backward	O
mutation	O
rates	O
and	O
relative	O
fitness	O
of	O
various	O
mutational	O
groups	O
known	O
to	O
confer	O
HIV	B:C0019704
-	I:C0019704
1	I:C0019704
drug	O
resistance	I:C0013203
.	O

We	O
estimate	O
the	O
backward	O
mutation	O
rates	O
and	O
relative	O
fitness	O
of	O
various	O
mutational	O
groups	O
known	O
to	O
confer	O
HIV	O
-	I:C0019704
1	I:C0019704
drug	B:C0013203
resistance	I:C0013203
.	O

We	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	O
model	O
to	O
data	O
for	O
individuals	B:C0237401
who	O
were	O
originally	O
infected	O
by	O
an	O
HIV	O
-	I:C0019704
1	I:C0019704
strain	O
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	O
resistance	I:C0013203
-	O
conferring	O
mutations	O
and	O
observed	O
over	O
a	O
period	O
of	O
time	O
to	O
see	O
whether	O
the	O
resistant	O
strain	O
is	O
replaced	O
.	O

We	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	O
model	O
to	O
data	O
for	O
individuals	O
who	O
were	O
originally	O
infected	B:C0439663
by	O
an	O
HIV	O
-	I:C0019704
1	I:C0019704
strain	O
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	O
resistance	I:C0013203
-	O
conferring	O
mutations	O
and	O
observed	O
over	O
a	O
period	O
of	O
time	O
to	O
see	O
whether	O
the	O
resistant	O
strain	O
is	O
replaced	O
.	O

We	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	O
model	O
to	O
data	O
for	O
individuals	O
who	O
were	O
originally	O
infected	O
by	O
an	O
HIV	B:C0019704
-	I:C0019704
1	I:C0019704
strain	O
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	O
resistance	I:C0013203
-	O
conferring	O
mutations	O
and	O
observed	O
over	O
a	O
period	O
of	O
time	O
to	O
see	O
whether	O
the	O
resistant	O
strain	O
is	O
replaced	O
.	O

We	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	O
model	O
to	O
data	O
for	O
individuals	O
who	O
were	O
originally	O
infected	O
by	O
an	O
HIV	O
-	I:C0019704
1	I:C0019704
strain	O
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	B:C0013203
resistance	I:C0013203
-	O
conferring	O
mutations	O
and	O
observed	O
over	O
a	O
period	O
of	O
time	O
to	O
see	O
whether	O
the	O
resistant	O
strain	O
is	O
replaced	O
.	O

We	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	O
model	O
to	O
data	O
for	O
individuals	O
who	O
were	O
originally	O
infected	O
by	O
an	O
HIV	O
-	I:C0019704
1	I:C0019704
strain	O
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	O
resistance	I:C0013203
-	O
conferring	O
mutations	B:C0026882
and	O
observed	O
over	O
a	O
period	O
of	O
time	O
to	O
see	O
whether	O
the	O
resistant	O
strain	O
is	O
replaced	O
.	O

To	O
do	O
this	O
,	O
we	O
seek	O
a	O
distribution	O
,	O
generated	O
from	O
simulations	B:C0679083
of	O
the	O
stochastic	O
model	O
,	O
that	O
best	O
describes	O
the	O
observed	O
(	O
clinical	O
data	I:C1516606
)	O
replacement	O
times	O
of	O
a	O
given	O
mutation	O
.	O

To	O
do	O
this	O
,	O
we	O
seek	O
a	O
distribution	O
,	O
generated	O
from	O
simulations	O
of	O
the	O
stochastic	O
model	O
,	O
that	O
best	O
describes	O
the	O
observed	O
(	O
clinical	B:C1516606
data	I:C1516606
)	O
replacement	O
times	O
of	O
a	O
given	O
mutation	O
.	O

To	O
do	O
this	O
,	O
we	O
seek	O
a	O
distribution	O
,	O
generated	O
from	O
simulations	O
of	O
the	O
stochastic	O
model	O
,	O
that	O
best	O
describes	O
the	O
observed	O
(	O
clinical	O
data	I:C1516606
)	O
replacement	O
times	O
of	O
a	O
given	O
mutation	B:C0026882
.	O

We	O
found	O
that	O
Lamivudine	O
/	O
Emtricitabine	O
-	O
associated	O
mutations	B:C0026882
have	O
a	O
distinctly	O
higher	O
,	O
backward	O
mutation	O
rate	O
and	O
low	O
relative	O
fitness	O
compared	O
to	O
the	O
other	O
classes	O
(	O
as	O
has	O
been	O
reported	O
before	O
)	O
while	O
protease	O
inhibitors	I:C0033607
-	O
associated	O
mutations	O
have	O
a	O
slower	O
backward	O
mutation	O
rate	O
and	O
high	O
relative	O
fitness	O
.	O

We	O
found	O
that	O
Lamivudine	O
/	O
Emtricitabine	O
-	O
associated	O
mutations	O
have	O
a	O
distinctly	O
higher	O
,	O
backward	B:C0439784
mutation	O
rate	O
and	O
low	O
relative	O
fitness	O
compared	O
to	O
the	O
other	O
classes	O
(	O
as	O
has	O
been	O
reported	O
before	O
)	O
while	O
protease	O
inhibitors	I:C0033607
-	O
associated	O
mutations	O
have	O
a	O
slower	O
backward	O
mutation	O
rate	O
and	O
high	O
relative	O
fitness	O
.	O

We	O
found	O
that	O
Lamivudine	O
/	O
Emtricitabine	O
-	O
associated	O
mutations	O
have	O
a	O
distinctly	O
higher	O
,	O
backward	O
mutation	O
rate	O
and	O
low	O
relative	O
fitness	O
compared	O
to	O
the	O
other	O
classes	B:C0456387
(	O
as	O
has	O
been	O
reported	O
before	O
)	O
while	O
protease	O
inhibitors	I:C0033607
-	O
associated	O
mutations	O
have	O
a	O
slower	O
backward	O
mutation	O
rate	O
and	O
high	O
relative	O
fitness	O
.	O

We	O
found	O
that	O
Lamivudine	O
/	O
Emtricitabine	O
-	O
associated	O
mutations	O
have	O
a	O
distinctly	O
higher	O
,	O
backward	O
mutation	O
rate	O
and	O
low	O
relative	O
fitness	O
compared	O
to	O
the	O
other	O
classes	O
(	O
as	O
has	O
been	O
reported	O
before	O
)	O
while	O
protease	B:C0033607
inhibitors	I:C0033607
-	O
associated	O
mutations	O
have	O
a	O
slower	O
backward	O
mutation	O
rate	O
and	O
high	O
relative	O
fitness	O
.	O

We	O
found	O
that	O
Lamivudine	O
/	O
Emtricitabine	O
-	O
associated	O
mutations	O
have	O
a	O
distinctly	O
higher	O
,	O
backward	O
mutation	O
rate	O
and	O
low	O
relative	O
fitness	O
compared	O
to	O
the	O
other	O
classes	O
(	O
as	O
has	O
been	O
reported	O
before	O
)	O
while	O
protease	O
inhibitors	I:C0033607
-	O
associated	O
mutations	B:C0026882
have	O
a	O
slower	O
backward	O
mutation	O
rate	O
and	O
high	O
relative	O
fitness	O
.	O

We	O
found	O
that	O
Lamivudine	O
/	O
Emtricitabine	O
-	O
associated	O
mutations	O
have	O
a	O
distinctly	O
higher	O
,	O
backward	O
mutation	O
rate	O
and	O
low	O
relative	O
fitness	O
compared	O
to	O
the	O
other	O
classes	O
(	O
as	O
has	O
been	O
reported	O
before	O
)	O
while	O
protease	O
inhibitors	I:C0033607
-	O
associated	O
mutations	O
have	O
a	O
slower	O
backward	B:C0439784
mutation	O
rate	O
and	O
high	O
relative	O
fitness	O
.	O

For	O
the	O
other	O
mutation	B:C0026882
classes	O
,	O
we	O
found	O
more	O
uncertainty	O
in	O
their	O
estimates	O
.	O

For	O
the	O
other	O
mutation	O
classes	B:C0456387
,	O
we	O
found	O
more	O
uncertainty	O
in	O
their	O
estimates	O
.	O

